Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Nijland, Hanneke M. J.; Ruslami, Rovina; Suroto, A. Juwono; Burger, David M.; Alisjahbana, Bachti; Crevel, Reinout van; Aarnoutse, Rob E.

doi:10.1086/521894

Cited by 152 publications

(139 citation statements)

References 32 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Of all quinolones, moxifloxacin is considered the most promising antituberculosis drug (3,9,14). As a result, in vitro DST for this drug has become an important issue.…”

Section: Discussionmentioning

confidence: 99%

Comparative Study on Genotypic and Phenotypic Second-Line Drug Resistance Testing of Mycobacterium tuberculosis Complex Isolates

et al. 2010

View full text Add to dashboard Cite

The mycobacterium growth indicator tube (MGIT960) automated liquid medium testing method is becoming the international gold standard for second-line drug susceptibility testing of multidrug-and extensively drug-resistant Mycobacterium tuberculosis complex isolates. We performed a comparative study of the current gold standard in the Netherlands, the Middlebrook 7H10 agar dilution method, the MGIT960 system, and the GenoType MTBDRsl genotypic method for rapid screening of aminoglycoside and fluoroquinolone resistance. We selected 28 clinical multidrug-and extensively drug-resistant M. tuberculosis complex strains and M. tuberculosis H37Rv. We included amikacin, capreomycin, moxifloxacin, prothionamide, clofazimine, linezolid, and rifabutin in the phenotypic test panels. For prothionamide and moxifloxacin, the various proposed breakpoint concentrations were tested by using the MGIT960 method. The MGIT960 method yielded results 10 days faster than the agar dilution method. For amikacin, capreomycin, linezolid, and rifabutin, results obtained by all methods were fully concordant. Applying a breakpoint of 0.5 g/ml for moxifloxacin led to results concordant with those of both the agar dilution method and the genotypic method. For prothionamide, concordance was noted only at the lowest and highest MICs. The phenotypic methods yielded largely identical results, except for those for prothionamide. Our study supports the following breakpoints for the MGIT960 method: 1 g/ml for amikacin, linezolid, and clofazimine, 0.5 g/ml for moxifloxacin and rifabutin, and 2.5 g/ml for capreomycin. No breakpoint was previously proposed for clofazimine. For prothionamide, a division into susceptible, intermediate, and resistant seems warranted, although the boundaries require additional study. The genotypic assay proved a reliable and rapid method for predicting aminoglycoside and fluoroquinolone resistance.The emergence of multidrug-resistant tuberculosis (MDR-TB) in the 1990s, and more recently, extensively drug resistant tuberculosis (XDR-TB), has revealed the need for new drugs and alternative, second-line treatment regimens. Many of these second-line drugs are either old drugs that had not been frequently used because of side effects or unproven efficacy or newer drugs intended primarily for treatment of other infections (3). Their use necessitated an evaluation of drug susceptibility testing (DST) and a determination of the critical concentrations of these alternative drugs.A variety of techniques are now available for second-line DST, of which the mycobacterium growth indicator tube automated liquid culture system (MGIT960) is probably the most used and best validated at this moment (13). The latest addition to second-line DST are genotypic methods, which detect mutations in the gyrA gene of Mycobacterium tuberculosis that are associated with fluoroquinolone resistance and mutations in the rrs operon that are associated with resistance to capreomycin and the aminoglycosides (2-5).Despite the arrival of these novel tools, many unce...

show abstract

“…Of all quinolones, moxifloxacin is considered the most promising antituberculosis drug (3,9,14). As a result, in vitro DST for this drug has become an important issue.…”

Section: Discussionmentioning

confidence: 99%

Comparative Study on Genotypic and Phenotypic Second-Line Drug Resistance Testing of Mycobacterium tuberculosis Complex Isolates

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Taken together, these pharmacokinetic parameters suggest that moxifloxacin is ideal for daily dosing. It should be noted that co-administration of moxifloxacin and rifampicin reduced the plasma concentrations of moxifloxacin [24], and this must be considered in TB regimens that contain rifampicin.…”

Section: Pharmacokineticsmentioning

confidence: 99%

The role of moxifloxacin in tuberculosis therapy

Gillespie

2016

Eur Respir Rev

View full text Add to dashboard Cite

Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate this treatment and discontinue therapy, increasing the risk of resistance. There is a growing tide of multidrug resistance and few effective antibiotics to tackle the problem. Since the turn of the millennium there has been a surge in interest in developing new therapies for TB and a number of new drugs have been developed. In this review the repurposing of moxifloxacin, an 8-methoxy-fluoroquinolone, for TB treatment is discussed. The evidence that underpins the development of this agent is reviewed. The results of the recently completed phase III trials are summarised and the reasons for the unexpected outcome are explored. Finally, the design of new trials that incorporate moxifloxacin, and that address both susceptible disease and multidrug resistance, is described. @ERSpublications A review of the role of moxifloxacin in tuberculosis therapy http://ow.ly/WaAyC

show abstract

“…Empirical use of the newer FQs may also mask the diagnosis of TB, with a resultant delay in the start of treatment and a poor outcome [60]. Another concern is the interaction of moxifloxacin and gatifloxacin with rifampicin, resulting in potential attenuation of the efficacy of the former FQ [61], and a potentially increased risk of toxicity for the latter FQ [62].…”

Section: Safety/tolerance Of Newer Fqsmentioning

confidence: 99%

An Overview on Fluoroquinolone Drugs for the Treatment of Tubercular Infection

Asif¹

2017

IJBSBE

View full text Add to dashboard Cite

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Cited by 152 publications

References 32 publications

Comparative Study on Genotypic and Phenotypic Second-Line Drug Resistance Testing of Mycobacterium tuberculosis Complex Isolates

Comparative Study on Genotypic and Phenotypic Second-Line Drug Resistance Testing of Mycobacterium tuberculosis Complex Isolates

The role of moxifloxacin in tuberculosis therapy

An Overview on Fluoroquinolone Drugs for the Treatment of Tubercular Infection

Contact Info

Product

Resources

About